Back to top
more

Biohaven Ltd. (BHVN)

(Real Time Quote from BATS)

$37.95 USD

37.95
265,940

-0.59 (-1.53%)

Updated Apr 26, 2024 11:47 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead

by Zacks Equity Research

Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study

by Zacks Equity Research

The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.

Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study

by Zacks Equity Research

Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.

Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View

by Zacks Equity Research

Novavax (NVAX) reports better-than-expected third-quarter results, with earnings and revenues beating estimates. It lowers product sales guidance for 2023.

Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View

by Zacks Equity Research

Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.

Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs

by Zacks Equity Research

Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.

Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going

by Zacks Equity Research

Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strategic executions on the United States and the international fronts are likely to drive Walgreens (WBA) Q4 revenues.

Here's What Could Help Biohaven Ltd. (BHVN) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug

by Zacks Equity Research

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.

Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More

by Zacks Equity Research

Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.

Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates

by Zacks Equity Research

At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.

Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.

Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders

by Zacks Equity Research

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.

Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret

by Zacks Equity Research

Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition of Biohaven. Zavzpret provides migraine patients access to a fast-acting pain-relief option.

Why Earnings Season Could Be Great for Biohaven (BHVN)

by Zacks Equity Research

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VTWO

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWM

After Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Biohaven Ltd. (BHVN)

by Zacks Equity Research

Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 54%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Biohaven Ltd. (BHVN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biohaven Ltd. (BHVN) delivered earnings and revenue surprises of 30.83% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?